Delving into the Latest Updates on FP-01 with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms

Flunisyn

Target

CD4 x CD8

Mechanism

CD4 modulators(T-cell surface antigen CD4 modulators), CD8 modulators(Cluster of differentiation 8 modulators)

Therapeutic Areas

Respiratory DiseasesInfectious Diseases

Active Indication-

Inactive Indication

Influenza A virus infectionRefractory chronic cough

Originator Organization

Altimmune, Inc.

Active Organization-

Inactive Organization

Avalo Therapeutics, Inc.

Altimmune UK Ltd.

Altimmune, Inc.

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

A Randomised, Double Blind, Double Observer Study to Assess Repeated Administration of a Single Dose of an Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Dose of a Trivalent Inactivated Influenza Virus Vaccine in Subjects 65 to 74 Years of Age.

This study will evaluate the safety and immunogenicity of FP-01.1 and FP-01.1 reformulated with an adjuvant (FP-01.1-Adjuvant) in relatively healthy subjects 65 to 74 years of age, subjects that are more representative of the target population. Both formulations will be administered alone or concomitantly with the Trivalent Inactivated Influenza Virus (TIV) vaccine.

Start Date01 Sep 2012

Sponsor / Collaborator

Altimmune UK Ltd.

NCT01597349 / CompletedPhase 2

An Exploratory, Randomized, Placebo Controlled, Double Blind, Parallel Arm Dose Ranging Study to Determine the Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection

The purpose of this research study is to learn how effective and safe FP01 lozenges are when given to subjects with a cough due to an upper respiratory tract infection. The study will include subjects who have an upper respiratory tract infection, with a cough of less than six weeks duration.

Start Date01 May 2012

Sponsor / Collaborator

Avalo Therapeutics, Inc.

100 Clinical Results associated with FP-01

Login to view more data

100 Translational Medicine associated with FP-01

Login to view more data

100 Patents (Medical) associated with FP-01

Login to view more data

14

Literatures (Medical) associated with FP-01

01 Feb 2023·Luminescence

A highly sensitive ratiometric fluorescent probe based on fluorescein coumarin for detecting hydrazine in actual water and biological samples

Article

Author: Diao, Quanping ; Lv, Linlin ; Luo, Weiwei ; Ma, Pinyi ; Zhou, Yixiao ; Li, Tiechun ; Song, Daqian

AbstractHydrazine (N2H4) is a highly toxic and harmful chemical reagent. Fluorescent probes are simple and efficient tools for sensitive monitoring of N2H4 enrichment in the environment, humans, animals, and plants. In this work, a ratiometric fluorescent probe (FP‐1) containing coumarin was used for hydrazine detection. The proposed FP‐1 probe had a linear detection range of 0–250 μM and a limit of detection (LOD) of 0.059 μM (1.89 ppb). A large red Stokes shift was observed in fluorescence and UV–vis absorption spectra due to the hydrolysis of ester bonds between FP‐1 and hydrazine. The hydrazine detection mechanism of FP‐1 was also investigated using density functional theory (DFT) calculations. Finally, FP‐1 could sensitively and selectively monitor hydrazine in actual water samples and BEAS‐2B cells. Therefore, it has great application potential in environmental monitoring and disease diagnosis.

01 Sep 2022·Journal of Molecular RecognitionQ4 · BIOLOGY

Computational design of immunogenic peptide constructs comprising multiple human leukocyte antigen restricted dengue virus envelope epitopes

Q4 · BIOLOGY

Article

Author: Kaushal, Neha ; Jain, Sahil ; Baranwal, Manoj

AbstractDengue virus (DENV) is endemic in 100 countries with the ability to impact nearly 50% of world population. DENV envelope (E) protein is responsible for viral attachment to host cells and has been target of various countermeasure development efforts. The current study focuses on a consensus computational approach to identify cross‐reactive, immunogenic DENV‐2 E peptides displaying promiscuity with a wide array of human leukocyte antigen (HLA) molecules. Four conserved peptides (FP‐1, FP‐2, FP‐3 and FP‐4) containing multiple CD8+ and CD4+ T cell epitopes were identified by employment of various immunoinformatics tools. FP‐1, FP‐2, FP‐3 and FP‐4 were estimated to bind with 227, 1787, 1008 and 834 HLA alleles, respectively. Root mean square deviation (RMSD) values obtained by molecular docking (CABS‐Dock) with 20 HLA alleles (10 each of HLA classes I and II) resulted into comparable RMSD values of identified epitopes with native peptides, which represents the natural presentation of epitopes to HLA molecules. These peptides were also found to be part of previous experimentally validated immunogenic peptides. Further, a dengue immunogenic peptide construct was generated by linking the four peptides, an adjuvant and a 6× histidine tag. The construct showed strong binding and stability with Toll‐like receptor. Collectively, these results provide strong evidence in the support of the immunogenic potential of the dengue immunogenic peptide construct.

16 Aug 2022·ACS Omega

Efficient Process for the Production of Alkyl Esters

Article

Author: Chaudhari, Pankaj ; Nagarkar, Rahul A. ; Mal, Nawal Kishor ; Dapurkar, Sudhir E. ; Nagabhushana, Kyatanahalli S.

This article reports a scalable process development for the production of alkyl esters through the esterification route by utilizing fly ash as a catalyst. The catalyst consisting of mixed oxides such as alumina, iron oxide, calcium oxide, magnesium oxide, and silica was employed for the esterification reaction without modification. The catalyst was evaluated for the conversion of feedstock containing variable amounts of free fatty acids, mono/dibasic acid, and alcohol/polyols into the corresponding alkyl esters. Three types of fly ash catalysts, viz., FS-1, FP-1, and FC-1, were chosen from three different industrial sources. Synthesis of dimethyl adipate was studied as a model reaction. FS-1 fly ash gave the highest yield of dimethyl adipate, whereas FC-1 gave a low yield of dimethyl adipate. The recyclability of FS-1 was evaluated for three cycles, and no loss of yield was observed. Furthermore, the catalyst FS-I was found to be capable of producing good yields for various esterification reactions with different substrates.

100 Deals associated with FP-01

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Refractory chronic cough	Phase 2	US	Avalo Therapeutics, Inc.	01 Nov 2012
Influenza A virus infection	Phase 2	GB	Altimmune, Inc.	-
Influenza A virus infection	Phase 2	GB	Altimmune, Inc.	-